Chet Billingsley will not fund Breast Cancer Immunotherapy research or companies.
He has already been thrown out of one cancer immunotherapy company.
What little income Mentor Capital inc. (MNTR) (MNTR.PK) has is used to pay Chet's $104, 000 annual salary.
He might buy a few shares in some companies and then claim he has an "index" to measure his "investing" strategy.
Chet is peddling hope.
His only "income" is getting people to buy new stock in Mentor.